Navigation Links
Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
Date:5/13/2008

(43,808) (19,483)

Interest income 897 1,091

Interest expense (3,787) (3,268)

Other expense (12) (3,069)

Gain on sale of product rights - 5,145

Net loss $(46,710) $(19,584)

Net loss per share, basic and

diluted $(1.97) $(851.48)

Weighted-average common shares used

in computing net loss per share, basic

and diluted 23,743 23

JAZZ PHARMACEUTICALS, INC.

SUMMARY OF PRODUCT SALES, NET

(In thousands)

(Unaudited)

Three Months Ended March 31,

2008 2007

Xyrem $11,341 $8,624

Antizol 2,643 2,636

Cystadane - 365

Total $13,984 $11,625

JAZZ PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

March 31, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $100,771 $102,945

Restricted cash 1,998 1,939

Mar
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medimetriks Pharmaceuticals, Inc. Begins Operations
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
3. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
5. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
6. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
7. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
8. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
9. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
10. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
11. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
Post Your Comments:
*Name:
*Comment:
*Email: